Intervention not reported
Anthropometric outcomes: median weight gain per day (g/kg/d) Defined as ((discharge weight − admission weight)/weight on admission)/days on treatment among children with no oedema and discharged as cured (Charle‐Cuellar 2021)c · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: number of children with normal or underweight WHZ on discharge Defined as WHZ > −2 (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
The intervention showed no clear difference in anthropometric outcomes: number of children with normal or… (low certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: number of children with WHZ in moderate wasting range on discharge Defined as WHZ between −3 and −2 (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
The intervention showed no clear difference in anthropometric outcomes: number of children with WHZ in moderate… (moderate certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: number of children with WHZ in severe wasting range on discharge Defined as WHZ < −3: Hussain 2021 · children aged > 6 months and ≤ 5 years with wasting
The intervention showed no clear difference in anthropometric outcomes: number of children with WHZ in severe… (moderate certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: number of children with MUAC ≥ 115 mm on discharge (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
The intervention showed no clear difference in anthropometric outcomes: number of children with MUAC ≥ 115 mm on… (moderate certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: weight gain per day (g/kg/day) Calculated as ((discharge weight − admission weight)/weight on admission)/days in treatment among recovered children (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
1 finding from 1 review
Intervention not reported
Potency/bioactivity parameters of human insulin · healthy physicians
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bibliometric scores · peer reviewers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Walking speedg ‐ overall analysis Measured using metres/second (m/s) and metres/minute (m/min). A higher score indicates faster walking. · adults following hip fracture surgery
The intervention leads to higher walking speedg ‐ overall analysis Measured using metres/second (m/s)… (high certainty).
1 finding from 1 review
Intervention not reported
Walking speedg ‐ overall analysis Measured using metres/second (m/s) and metres/minute (m/min). A higher score indicates faster walking. · adults following hip fracture surgery
The intervention showed no clear difference in walking speedg ‐ overall analysis Measured using metres/second (m/s)… (moderate certainty).
1 finding from 1 review
Menstrual blood loss: mean loss
Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) showed no clear difference in menstrual blood loss (alkaline hematin method) compared with placebo or active comparators (paracetamol, tranexamic acid); GRADE not reported.
2 findings from 1 review
MD 14.11
Studies not reported
GRADE not reported
MD 0.3
Studies not reported
GRADE not reported
Menstrual blood loss % occurrence of heavy menstrual bleeding (alkaline hematin method)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Menstrual blood loss: mean loss
1 finding from 1 review
Time for laboratory parameters to normalise: CRP, ESR (days) Duration: N/A · children diagnosed with Kawasaki disease
1 finding from 1 review
Quality of life immediately after the intervention · people with Parkinson's disease
1 finding from 1 review
Scar severity ‐ Helium‐Neon (He‐Ne) laser plus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream versus decamethyltetrasiloxane, polydimethylsiloxane and cyclopentasiloxane cream ‐ Vancouver Scar scale (VSS) (higher scores... · participants with hypertrophic and keloid scars
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Morbidity (metabolic syndrome)d · children and adolescents with obesity
It is very uncertain whether the intervention changes morbidity (metabolic syndrome)d (very low certainty).
1 finding from 1 review
Motor performance Accelerometer, 3‐dimensional motion analysis system, number of acting · upper limb rehabilitation after stroke
1 finding from 1 review
Intervention not reported
Proportion of people with COPD diagnoses confirmed with spirometry · health professionals managing COPD
1 finding from 1 review
no estimate extracted
4 participants
Very low
Vascular access complications · CKD patients who underwent AVF creation
It is very uncertain whether upper limb exercise training changes vascular access complications (isometric versus isotonic exercise… compared with control (no intervention/usual care/isotonic exercise) (very low certainty).
1 finding from 1 review